Actively Recruiting
PHenotype-based RApid SEquencing of Guideline-directed Medical Therapy for Heart Failure With Reduced Ejection Fraction PHRASE-HF A Multicentre, Prospective, Non-interventional Study to Examine Outcomes of Rapid In-hospital Implementation of GDMT and Its Translation From Discharge Into Routine Care
Led by AstraZeneca · Updated on 2026-05-12
438
Participants Needed
6
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Heart failure with reduced ejection fraction HFrEF is a serious condition affecting many people worldwide and represents about half of all heart failure cases. This research aims to evaluate how well guideline-directed medical therapy GDMT is implemented in real-world hospital and outpatient settings after a specific physician training program within the German Helios hospital network. The study focuses on early in-hospital initiation and rapid up-titration of GDMT following the 2023 European Society of Cardiology guidelines, which recommend a combination of four drug classes to improve patient outcomes. The study observes patients hospitalized for HFrEF who receive treatment according to the Helios-GDMT program. Researchers will track the use and adjustment of recommended drug classes including ACE inhibitors, ARNI, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors from hospital admission through discharge and into routine outpatient care. The study is non-interventional and monitors how these guideline-based treatments are applied and maintained over time. Participants will be followed from hospital admission, with assessments around six days post-hospitalization at discharge, and then up to 12 months. Researchers will collect data on medication adherence, heart failure symptoms, rehospitalization, mortality, and patient-reported outcomes such as quality of life and health questionnaires. Regular post-discharge visits will be recorded, and changes in clinical measures like blood pressure, heart rate, and kidney function will be monitored to understand the real-world impact of the treatment program over one year.
CONDITIONS
Brief Title
Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at the time of signing the informed consent
- Hospitalized in a participating site with full inpatient treatment of at least 24 hours
- Diagnosed with heart failure with reduced ejection fraction (left ventricular ejection fraction 60%) according to ESC guidelines
- Treated with no more than two of the indicated drug classes (ACE-I/ARNI/ARB, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors) at admission
- Signed and dated informed consent before enrollment
- Willing and able to meet all study requirements as listed in the informed consent form
You will not qualify if you...
- Initial hospital presentation with cardiogenic shock or other types of shock
- History of heart transplantation
- Intolerance to one or more GDMT drug classes or significant side effects leading to stopping two or more drugs within one class (except ACE-I/ARB)
- Current or planned participation in another clinical trial
- Investigator decision that participation is unsuitable due to expected non-compliance
- Pregnancy or breastfeeding
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here